ResultsIQ

ResultsIQ › Latest results › Thyrocare Technologies Limited

Thyrocare Technologies Limited Q4 FY25 results deck summary

NSE: THYROCARE · BSE: 539871

Results deck of 23 Apr 2025, summarised by AI from the filing.

Consolidated revenue ₹187.2 cr (Q4 FY24: ₹154.2 cr, +21% YoY).

Key takeaways

  1. Q4 revenue Consolidated revenue ₹187.2 cr (Q4 FY24: ₹154.2 cr, +21% YoY).
  2. Normalized EBITDA Q4 FY25 normalized EBITDA ₹65.3 cr (Q4 FY24: ₹36.7 cr, +78% YoY).
  3. Acquisitions Completed acquisitions of Polo Labs and Vimta clinical diagnostics business during FY25.
  4. ESOP impact Reported EBITDA impacted by ESOP cost of ₹20.7 cr in FY25.

Original filing on BSE

Thyrocare Technologies Limited Q1 FY27 results

As filed: Revenue ₹240 cr (+24% year on year), EBITDA ₹77.3 cr (+36% year on year), PAT ₹51.3 cr (+35% year on year), EBITDA margin 32.2% (+266 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹224 cr (+20% year on year), EBITDA ₹75.1 cr (+29% year on year), PAT ₹48.7 cr (+121% year on year), EBITDA margin 33.5% (+251 bps). Score 56 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well above it. EBITDA margin rose 251 bps year on year. Revenue rose ₹36.9 cr on a year ago, more than the ₹33.0 cr it added the year before. Share price after the results: +10.0% in 29 days (Nifty 500: −3.2%).
  • Q3 FY26: Revenue ₹196 cr (+18% year on year), EBITDA ₹57.8 cr (+38% year on year), PAT ₹28.1 cr (+47% year on year), EBITDA margin 29.6% (+427 bps). Score 63 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 427 bps year on year. Revenue fell 10% from last quarter. Profit before exceptional items rose ₹13.3 cr on a year ago, more than the ₹8.0 cr it added the year before. Share price after the results: −9.7% in 30 days (Nifty 500: +1.5%).
  • Q2 FY26: Revenue ₹217 cr (+23% year on year), EBITDA ₹72.0 cr (+50% year on year), PAT ₹48.0 cr (+2% year on year), EBITDA margin 33.2% (+606 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well below it. EBITDA margin rose 606 bps year on year. Share price after the results: +12.1% in 29 days (Nifty 500: +2.2%).
  • Q1 FY26: Revenue ₹193 cr (+23% year on year), EBITDA ₹57.0 cr (+36% year on year), PAT ₹38.0 cr (+58% year on year), EBITDA margin 29.5% (+278 bps). Score 79 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 278 bps year on year. Revenue rose ₹36.0 cr on a year ago, more than the ₹22.0 cr it added the year before. Share price after the results: +15.5% in 29 days (Nifty 500: −3.4%).
  • Q4 FY25: Revenue ₹187 cr (+21% year on year), EBITDA ₹58.0 cr (+71% year on year), PAT ₹22.0 cr (+29% year on year), EBITDA margin 31.0% (+894 bps). Score 77 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was below it. EBITDA margin rose 894 bps year on year. Tax rate 52%. Revenue rose ₹33.0 cr on a year ago, more than the ₹18.0 cr it added the year before. Share price after the results: +39.3% in 30 days (Nifty 500: +7.1%).
  • Q3 FY25: Revenue ₹166 cr (+23% year on year), EBITDA ₹42.0 cr (+35% year on year), PAT ₹19.0 cr (+27% year on year), EBITDA margin 25.3% (+234 bps). Score 66 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 234 bps year on year. Revenue fell 6% from last quarter.
  • Q2 FY25: Revenue ₹177 cr (+20% year on year), EBITDA ₹48.0 cr (+26% year on year), PAT ₹47.0 cr (+135% year on year), EBITDA margin 27.1% (+144 bps). Score 74 of 100, Above trend. EBITDA margin rose 144 bps year on year. Tax rate -27%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Thyrocare Technologies Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.